Dr. Reddys Laboratories is currently trading at Rs. 2258.50, up by 2.90 points or 0.13% from its previous closing of Rs. 2255.60 on the BSE.
The scrip opened at Rs. 2267.00 and has touched a high and low of Rs. 2286.70 and Rs. 2253.00 respectively. So far 28781 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3203.95 on 06-Jan-2017 and a 52 week low of Rs. 1901.65 on 11-Aug-2017.
Last one week high and low of the scrip stood at Rs. 2328.00 and Rs. 2175.00 respectively. The current market cap of the company is Rs. 37457.34 crore.
The promoters holding in the company stood at 26.77%, while Institutions and Non-Institutions held 43.15% and 15.25% respectively.
Dr. Reddy’s Laboratories has received the Establishment Inspection Report (EIR) from the US Food & Drug Administration (USFDA) for its Formulations Manufacturing Plant - 3 at Bachupally, Hyderabad as closure of audit.
Earlier in April, USFDA had inspected the Formulations Manufacturing Plant - 3 wherein it had issued a form 483 with 11 observations.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1515.45 |
Dr. Reddys Lab | 6122.65 |
Cipla | 1520.65 |
Zydus Lifesciences | 1080.85 |
Lupin | 1624.95 |
View more.. |